DENTAL-BIO™
Microbiome-oriented oral care platform.
- Product family
- 3 complementary formats
- Planned market availability
- Q4 2026
- Seeking
- Distribution Partners

Our commercialization-ready portfolio launches across Q4 2026 and Q1 2027. Alongside it, ACS is developing a next-generation oral-health platform, as well as selected pharmaceutical and MedTech development programs.
Alongside its pharmaceutical and medical technology pipeline, ACS Biomed is developing differentiated healthcare platforms whose formulations and positioning have already been defined and which are entering the next phase of sampling, industrialization and commercial development.
Microbiome-oriented oral care platform.

A next-generation oral-gel platform under development combining water-free formulation technology, mucoadhesive delivery and microbiome-focused functional components.
Women’s vitality platform segmented by life stage.

Specialist system for women’s intimate wellbeing.

Functional topical platform for everyday mobility and comfort.

Multi-active platform for men’s vitality across different life stages.
